
Raywatt, a South Korean medical imaging specialist led by CEO Ha Jin-yong, made a strong impression at the recent Transcatheter Cardiovascular Therapeutics (TCT 2026) conference in San Diego. Running from October 31 to November 3, the premier global gathering served as a stage for Raywatt to highlight its flagship cardiovascular optical coherence tomography (OCT) platform, ‘FASTER.’
Operating an independent exhibition space, the company drew industry attention by debuting ‘FASTER-TealGold™,’ an adaptive color map designed to optimize vascular visibility. By utilizing distinct Teal and Gold shades based on pixel intensity and vessel boundaries, the new feature clearly differentiates superficial vessel layers from deeper anatomical structures.
Academic Validation and Automation Breakthroughs
Raywatt’s innovations also took center stage during several key academic sessions. On November 1, Professor Jung-sun Kim of Yonsei University’s Severance Cardiovascular Hospital delivered a presentation titled “AI-Triggered OCT System With Closed-Loop Contrast Injector at 400 Frames per Second.” His presentation spotlighted ‘AutoFlow™,’ Raywatt’s proprietary AI-driven automation tool that seamlessly links injector management with image capture. The technology promises to streamline the diagnostic workflow, elevate user convenience, and significantly lower contrast media requirements at an ultra-fast rate of 400 frames per second.
Furthermore, on November 2, Professor Hong-ki Jeon shared promising clinical data assessing the feasibility of saline-based, ultra-high-speed OCT in human subjects, reinforcing the growing clinical viability of Raywatt’s hardware and software solutions.
Expanding Global Footprint
Beyond presentations and product displays, the Raywatt delegation engaged in a series of strategic networking sessions. Leadership met with international medical device executives, clinical Key Opinion Leaders (KOLs), and prospective partners to explore cross-border collaborations and distribution channels.
Looking ahead, Raywatt aims to build on this momentum by pursuing U.S. Food and Drug Administration (FDA) regulatory approvals and solidifying international partnerships to accelerate its worldwide market penetration.
“TCT 2026 provided an invaluable platform to demonstrate our next-generation technologies and clinical breakthroughs directly to the global cardiovascular community,” remarked CEO Ha Jin-yong. “We remain committed to driving continuous innovation and rigorous clinical validation to cement our position as a leader in the global vascular imaging market.”
[Copyright (c) Global Economic Times. All Rights Reserved.]





























